Nicolas Tournier

List of Publications by Year
in descending order

72	1,465	331259 21	377514 34
papers	citations	h-index	g-index

87	87	87	1738
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2). International Journal of Neuropsychopharmacology, 2010, 13, 905-915.	1.0	108
2	Opioid Transport by ATP-Binding Cassette Transporters at the Blood-Brain Barrier: Implications for Neuropsychopharmacology. Current Pharmaceutical Design, 2011, 17, 2829-2842.	0.9	63
3	Preparation and Stability of Voriconazole Eye Drop Solution. Antimicrobial Agents and Chemotherapy, 2009, 53, 798-799.	1.4	62
4	Simultaneous Determination of Eight Î²-Lactam Antibiotics, Amoxicillin, Cefazolin, Cefepime, Cefotaxime, Ceftazidime, Cloxacillin, Oxacillin, and Piperacillin, in Human Plasma by Using Ultra-High-Performance Liquid Chromatography with Ultraviolet Detection. Antimicrobial Agents and Chemotherapy, 2016, 60, 4734-4742.	1.4	59
5	Respiratory toxicity of buprenorphine results from the blockage of P-glycoprotein-mediated efflux of norbuprenorphine at the bloodâ€“brain barrier in mice. Critical Care Medicine, 2012, 40, 3215-3223.	0.4	58
6	Imaging techniques to study drug transporter function in vivo. , 2018, 189, 104-122.		57
7	Bloodâ€“brain and retinal barriers show dissimilar ABC transporter impacts and concealed effect of Pâ€glycoprotein on a novel verapamil influx carrier. British Journal of Pharmacology, 2016, 173, 497-510.	2.7	50
8	Effects of Selected OATP and/or ABC Transporter Inhibitors on the Brain and Whole-Body Distribution of Glyburide. AAPS Journal, 2013, 15, 1082-1090.	2.2	49
9	Imaging the Impact of the P-Glycoprotein (ABCB1) Function on the Brain Kinetics of Metoclopramide. Journal of Nuclear Medicine, 2016, 57, 309-314.	2.8	47
10	Transport of Selected PET Radiotracers by Human P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2): An In Vitro Screening. Journal of Nuclear Medicine, 2011, 52, 415-423.	2.8	43
11	Strategies to Inhibit ABCB1- and ABCG2-Mediated Efflux Transport of Erlotinib at the Bloodâ€“Brain Barrier: A PET Study on Nonhuman Primates. Journal of Nuclear Medicine, 2017, 58, 117-122.	2.8	43
12	Proof-of-Concept Study of Drug Brain Permeability Between in Vivo Human Brain and an in Vitro iPSCs-Human Blood-Brain Barrier Model. Scientific Reports, 2019, 9, 16310.	1.6	42
13	P-Glycoprotein (ABCB1) Inhibits the Influx and Increases the Efflux of ¹¹C-Metoclopramide Across the Bloodâ€“Brain Barrier: A PET Study on Nonhuman Primates. Journal of Nuclear Medicine, 2018, 59, 1609-1615.	2.8	39
14	Impact of P-Glycoprotein Function on the Brain Kinetics of the Weak Substrate ¹¹C-Metoclopramide Assessed with PET Imaging in Humans. Journal of Nuclear Medicine, 2019, 60, 985-991.	2.8	38
15	Impact of blood-brain barrier permeabilization induced by ultrasound associated to microbubbles on the brain delivery and kinetics of cetuximab: An immunoPET study using 89Zr-cetuximab. Journal of Controlled Release, 2020, 328, 304-312.	4.8	38
16	Physical blood-brain barrier disruption induced by focused ultrasound does not overcome the transporter-mediated efflux of erlotinib. Journal of Controlled Release, 2018, 292, 210-220.	4.8	37
17	Repurposing radiotracers for myelin imaging: a study comparing 18F-florbetaben, 18F-florbetapir, 18F-flutemetamol,11C-MeDAS, and 11C-PiB. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 490-501.	3.3	34
18	Discrepancies in the P-glycoprotein-Mediated Transport of 18F-MPPF: A Pharmacokinetic Study in Mice and Non-human Primates. Pharmaceutical Research, 2012, 29, 2468-2476.	1.7	27

#	Article	IF	Citations
19	Imaging Pâ€Glycoprotein Function at the Bloodâ€“Brain Barrier as a Determinant of the Variability in Response to Central Nervous System Drugs. Clinical Pharmacology and Therapeutics, 2019, 105, 1061-1064.	2.3	25
20	A Proof-of-Concept Study to Inhibit ABCG2- and ABCB1-Mediated Efflux Transport at the Human Bloodâ€“Brain Barrier. Journal of Nuclear Medicine, 2019, 60, 486-491.	2.8	25
21	Assessment of P-Glycoprotein Transport Activity at the Human Bloodâ€“Retina Barrier with (R)â€¹¹C-Verapamil PET. Journal of Nuclear Medicine, 2017, 58, 678-681.	2.8	23
22	Imaging the neuroimmune response to alcohol exposure in adolescent baboons: a TSPO PET study using ¹⁸Fâ€DPAâ€714. Addiction Biology, 2018, 23, 1000-1009.	1.4	23
23	Imaging P-Glycoprotein Induction at the Bloodâ€“Brain Barrier of a Î²-Amyloidosis Mouse Model with ¹¹C-Metoclopramide PET. Journal of Nuclear Medicine, 2020, 61, 1050-1057.	2.8	21
24	Inhibition of ABCB1 and ABCG2 at the Mouse Bloodâ€“Brain Barrier with Marketed Drugs To Improve Brain Delivery of the Model ABCB1/ABCG2 Substrate [¹¹C]erlotinib. Molecular Pharmaceutics, 2019, 16, 1282-1293.	2.3	20
25	Glacier fluctuations during the Late Glacial and Holocene on the AriÃ¨ge valley, northern slope of the Pyrenees and reconstructed climatic conditions. Mediterranean Geoscience Reviews, 2020, 2, 37-51.	0.6	20
26	Determination of atazanavir in human plasma using solid-phase extraction and high-performance liquid chromatography. Journal of Pharmaceutical and Biomedical Analysis, 2005, 39, 791-795.	1.4	19
27	Changes in dipole membrane potential at the mouse bloodâ€“brain barrier enhance the transport of ^{99m}Technetium Sestamibi more than inhibiting Abcb1, Abcc1, or Abcg2. Journal of Neurochemistry, 2009, 108, 767-775.	2.1	19
28	Validation of a simple HPLC-UV method for rifampicin determination in plasma: Application to the study of rifampicin arteriovenous concentration gradient. Journal of Pharmaceutical and Biomedical Analysis, 2016, 123, 173-178.	1.4	18
29	Cortico-Amygdala-Striatal Activation by Modafinil/Flecainide Combination. International Journal of Neuropsychopharmacology, 2018, 21, 687-696.	1.0	17
30	Effect of Rifampicin on the Distribution of [¹¹C]Erlotinib to the Liver, a Translational PET Study in Humans and in Mice. Molecular Pharmaceutics, 2018, 15, 4589-4598.	2.3	17
31	Complete inhibition of ABCB1 and ABCG2 at the bloodâ€“brain barrier by co-infusion of erlotinib and tariquidar to improve brain delivery of the model ABCB1/ABCG2 substrate [¹¹C]erlotinib. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 1634-1646.	2.4	17
32	[18F]2-Fluoro-2-deoxy-sorbitol PET Imaging for Quantitative Monitoring of Enhanced Blood-Brain Barrier Permeability Induced by Focused Ultrasound. Pharmaceutics, 2021, 13, 1752.	2.0	17
33	Acute Morphine Exposure Increases the Brain Distribution of [¹⁸F]DPA-714, a PET Biomarker of Glial Activation in Nonhuman Primates. International Journal of Neuropsychopharmacology, 2017, 20, pyw077.	1.0	16
34	Diphenhydramine as a selective probe to study H⁺-antiporter function at the bloodâ€“brain barrier: Application to [¹¹C]diphenhydramine positron emission tomography imaging. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 2185-2195.	2.4	15
35	Gender and strain contributions to the variability of buprenorphine-related respiratory toxicity in mice. Toxicology, 2013, 305, 99-108.	2.0	14
36	Imaging Probes and Modalities for the Study of Solute Carrier O (SLCO)-Transport Function InÂVivo. Journal of Pharmaceutical Sciences, 2017, 106, 2335-2344.	1.6	14

#	Article	IF	Citations
37	Comparative vulnerability of PET radioligands to partial inhibition of P-glycoprotein at the blood-brain barrier: A criterion of choice?. Journal of Cerebral Blood Flow and Metabolism, 2022, 42, 175-185.	2.4	14
38	Differential influence of propofol and isoflurane anesthesia in a nonâ€human primate on the brain kinetics and binding of [¹⁸F]<scp>DPA</scp>â€714, a positron emission tomography imaging marker of glial activation. European Journal of Neuroscience, 2015, 42, 1738-1745.	1.2	13
39	Evaluation of TSPO PET imaging, a marker of glial activation, to study the neuroimmune footprints of morphine exposure and withdrawal. Drug and Alcohol Dependence, 2017, 170, 43-50.	1.6	13
40	Impaired Clearance From the Brain Increases the Brain Exposure to Metoclopramide in Elderly Subjects. Clinical Pharmacology and Therapeutics, 2021, 109, 754-761.	2.3	13
41	Imaging the impact of cyclosporin A and dipyridamole on P-glycoprotein (ABCB1) function at the blood-brain barrier: A [11C]-N-desmethyl-loperamide PET study in nonhuman primates. European Journal of Pharmaceutical Sciences, 2016, 91, 98-104.	1.9	12
42	Positron Emission Tomography Imaging Reveals an Importance of Saturable Liver Uptake Transport for the Pharmacokinetics of Metoclopramide. Contrast Media and Molecular Imaging, 2018, 2018, 1-8.	0.4	12
43	Ibogaine labeling with 99mTc-tricarbonyl: Synthesis and transport at the mouse bloodâ€“brain barrier. Journal of Pharmaceutical Sciences, 2009, 98, 4650-4660.	1.6	11
44	[11C]befloxatone brain kinetics is not influenced by Bcrp function at the bloodâ€“brain barrier: A PET study using Bcrp TGEM knockout rats. European Journal of Pharmaceutical Sciences, 2013, 50, 520-525.	1.9	10
45	Challenges and Perspectives of the Hybridization of PET with Functional MRI or Ultrasound for Neuroimaging. Neuroscience, 2021, 474, 80-93.	1.1	10
46	Pharmacokinetic neuroimaging to study the dose-related brain kinetics and target engagement of buprenorphine in vivo. Neuropsychopharmacology, 2021, 46, 1220-1228.	2.8	10
47	Comparative test-retest variability of outcome parameters derived from brain [18F]FDG PET studies in non-human primates. PLoS ONE, 2020, 15, e0240228.	1.1	9
48	Mechanisms of respiratory depression induced by the combination of buprenorphine and diazepam in rats. British Journal of Anaesthesia, 2022, 128, 584-595.	1.5	9
49	Impact of rifampicin-inhibitable transport on the liver distribution and tissue kinetics of erlotinib assessed with PET imaging in rats. EJNMMI Research, 2018, 8, 81.	1.1	8
50	¹¹ C-glyburide PET imaging unveils the negligible brain penetration of glyburide in humans. Neurology, 2019, 92, 813-814.	1.5	8
51	Nalmefene alleviates the neuroimmune response to repeated bingeâ€like ethanol exposure: A TSPO PET imaging study in adolescent rats. Addiction Biology, 2021, 26, e12962.	1.4	8
52	Intravenous infusion for the controlled exposure to the dual ABCB1 and ABCG2 inhibitor elacridar in nonhuman primates. Drug Delivery and Translational Research, 2018, 8, 536-542.	3.0	7
53	Validation of Pharmacological Protocols for Targeted Inhibition of Canalicular MRP2 Activity in Hepatocytes Using [99mTc]mebrofenin Imaging in Rats. Pharmaceutics, 2020, 12, 486.	2.0	7
54	Quantitative Tissue Pharmacokinetics and EPR Effect of AGuIX Nanoparticles: A Multimodal Imaging Study in an Orthotopic Glioblastoma Rat Model and Healthy Macaque. Advanced Healthcare Materials, 2021, 10, e2100656.	3.9	7

#	Article	IF	Citations
55	Influence of P-Glycoprotein Inhibition or Deficiency at the Bloodâ€“Brain Barrier on 18F-2-Fluoro-2-Deoxy-d-glucose (18F-FDG) Brain Kinetics. AAPS Journal, 2015, 17, 652-659.	2.2	6
56	ABCB1 and ABCG2 Together Limit the Distribution of ABCB1/ABCG2 Substrates to the Human Retina and the ABCG2 Single Nucleotide Polymorphism Q141K (c.421C> A) May Lead to Increased Drug Exposure. Frontiers in Pharmacology, 2021, 12, 698966.	1.6	6
57	An original radio-biomimetic approach to synthesize radiometabolites for PET imaging. Nuclear Medicine and Biology, 2020, 90-91, 10-14.	0.3	4
58	Automated two-step manufacturing of [11C]glyburide radiopharmaceutical for PET imaging in humans. Nuclear Medicine and Biology, 2020, 84-85, 20-27.	0.3	4
59	Repurposing 99mTc-Mebrofenin as a Probe for Molecular Imaging of Hepatocyte Transporters. Journal of Nuclear Medicine, 2021, 62, 1043-1047.	2.8	4
60	Impact of Acute Alcohol Exposure on Pâ€Glycoprotein Function at the Bloodâ€Brain Barrier Assessed Using 11 Câ€Metoclopramide PET Imaging. Clinical Pharmacology and Therapeutics, 2019, 105, 812-813.	2.3	3
61	Impact of Donepezil on Brain Glucose Metabolism Assessed Using [18F]2-Fluoro-2-deoxy-D-Glucose Positron Emission Tomography Imaging in a Mouse Model of Alzheimerâ€™s Disease Induced by Intracerebroventricular Injection of Amyloid-Beta Peptide. Frontiers in Neuroscience, 2022, 16, 835577.	1.4	3
62	Ventilatory depression following oral buprenorphine exposure: insight into the involved mechanisms. Clinical Toxicology, 2020, 59, 1-2.	0.8	2
63	Imaging-Based Characterization of a Slco2b1(-/-) Mouse Model Using [11C]Erlotinib and [99mTc]Mebrofenin as Probe Substrates. Pharmaceutics, 2021, 13, 918.	2.0	2
64	Pharmacokinetic Imaging Using 99mTc-Mebrofenin to Untangle the Pattern of Hepatocyte Transporter Disruptions Induced by Endotoxemia in Rats. Pharmaceuticals, 2022, 15, 392.	1.7	2
65	Isotopic Radiolabeling of the Antiretroviral Drug [18F]Dolutegravir for Pharmacokinetic PET Imaging. Pharmaceuticals, 2022, 15, 587.	1.7	2
66	Analysis of an EMST-based path for 3D meshes. CAD Computer Aided Design, 2015, 64, 22-32.	1.4	1
67	Influence of Cation Transporters (OCTs and MATEs) on the Renal and Hepatobiliary Disposition of [11C]Metoclopramide in Mice. Pharmaceutical Research, 2021, 38, 127-140.	1.7	1
68	BarriÃ¨re hÃ©mato-encÃ©phaliqueÂ: implication des transporteurs ABC en neuropharmacologie. Reanimation: Journal De La Societe De Reanimation De Langue Francaise, 2008, 17, 664-669.	0.1	0
69	Notice of Removal: Ultrasound-induced delivery of erlotinib to the brain is not enough to counter efflux pumps. , 2017, , .		0
70	Human Biodistribution and Radiation Dosimetry of the P-Glycoprotein Radiotracer [11C]Metoclopramide. Molecular Imaging and Biology, 2021, 23, 180-185.	1.3	0
71	Radiolabeling and brain penetration of [¹¹C]VU0071063, a ligand of type 1 sulfonylurea receptors for positron emission tomography imaging. Journal of Labelled Compounds and Radiopharmaceuticals, 2022, 65, 28-35.	0.5	0
72	Dynamic 4D PET Reconstruction Using the Spectral Model and Adaptive Residual Modelling. , 2020, , .		0